Arcutis Releases Zoryve Study Data Showing Good Safety Profile
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 10 2026
0mins
Should l Buy ARQT?
Arcutis Biotherapeutics announced that Pediatric Dermatology published data from the Phase 3 open-label extension study evaluating once-daily Zoryve cream 0.05% in children aged 2 to 5 years with mild-to-moderate atopic dermatitis. Data from the INTEGUMENT-OLE trial, which supported the FDA approval of Zoryve cream 0.05% in October 2025, demonstrated that Zoryve cream 0.05% is safe and well-tolerated, and efficacy was not only maintained but continued to improve with up to 56 weeks of treatment. The primary endpoint of the OLE study was safety. Treatment-Emergent Adverse Events were reported for 280 participants, and most events were mild or moderate. The most common TEAEs included upper respiratory tract infection in 8.7% of participants, nasopharyngitis in 5.0%, and pyrexia in 5.0%. Gastrointestinal adverse events were reported for 4.4% of participants, most commonly vomiting and diarrhea. Serious Adverse Events occurred in 18 participants, none of which were considered treatment-related. Overall, 14 of 562 participants experienced treatment-related AEs, and 4 participants experienced application site pain.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARQT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARQT
Wall Street analysts forecast ARQT stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 24.190
Low
30.00
Averages
32.00
High
37.00
Current: 24.190
Low
30.00
Averages
32.00
High
37.00
About ARQT
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech IPOs Show Strong Performance in Q1 2026
- Biotech Financing Trends: In Q1 2026, biotech companies raised a median of $287.5 million each, with nearly all possessing mid to late-stage clinical data, indicating a strong market focus on high-value science that boosts investor confidence and capital inflow.
- Industry Focus on High-Value Projects: The IQVIA report reveals that pharmaceutical R&D spending reached $159.1 billion in 2025, with companies redirecting resources toward validated late-stage programs, reflecting a market preference for credible pipelines that enhances the standing of biotech firms.
- Avaí Bio's Major Progress: Avaí Bio is set to present new data on its α-Klotho anti-aging therapy at the Second Annual Klotho Conference, being invited to speak alongside renowned researchers, which signifies an elevation in its influence within the Klotho space and may attract increased investor attention.
- Stoke Therapeutics' Breakthrough Results: Stoke Therapeutics published data on zorevunersen in The New England Journal of Medicine, demonstrating its potential disease-modifying effects in Dravet syndrome, which is expected to propel its Phase 3 EMPEROR study in 2027, further solidifying its market position.
See More
Arcutis Biotherapeutics Executive Sells Shares
- Insider Share Sale: Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics on April 1, 2026, for a total value of $239,000, reducing his direct holdings to 39,744 shares, indicating a significantly diminished capacity for future sales.
- Transaction Scale Analysis: This sale of 10,000 shares aligns with the typical monthly trading volume observed since 2023, reflecting a consistent selling pattern from Welgus, and it represents 20% of his direct holdings, highlighting a notable decrease in his ownership stake.
- Company Financial Performance: Arcutis generated $372.1 million in net product revenue in 2025, a 123% increase year-over-year, with fourth-quarter sales reaching $127.5 million, indicating significant progress in its commercialization efforts and improving financial quality.
- Market Outlook: With the successful launch of ZORYVE eczema cream, Arcutis is transitioning from a development phase to a commercial phase, with a regulatory submission planned for 2026, suggesting that long-term investors should focus on the company's accelerating commercialization and expanding indications.
See More
Arcutis Biotherapeutics Director Sells Shares
- Director Share Sale: Howard G. Welgus, a director at Arcutis Biotherapeutics, sold 10,000 shares on April 1, 2026, for a total of $239,000, representing 20.10% of his direct holdings, reducing his stake from 49,744 to 39,744 shares, indicating sustained confidence in the company's future.
- Transaction Context: This sale was executed under a pre-arranged 10b5-1 plan adopted in March 2025, suggesting it was a planned liquidity event rather than a reaction to market fluctuations, especially with the stock up about 65% over the past year.
- Strong Financial Performance: Arcutis generated $372.1 million in net product revenue in 2025, a 123% year-over-year increase, with fourth-quarter sales alone reaching $127.5 million, demonstrating robust momentum in its commercialization efforts and expectations for continued positive operating cash flow.
- Clinical Data Validation: Recent Phase 2 data for ZORYVE cream showed meaningful improvements in infant atopic dermatitis, with rapid itch relief and strong tolerability, supporting a planned regulatory submission in 2026, further solidifying its market position in dermatological treatments.
See More
Palvella Appoints New Senior Vice President of Sales
- Executive Appointment: Palvella Therapeutics has appointed Kent Taylor as Senior Vice President of Sales, bringing over 25 years of pharmaceutical experience, including successful launches of innovative therapies at Arcutis Biotherapeutics and Incyte, which is expected to significantly enhance Palvella's sales leadership and market insights.
- Market Potential: Taylor will lead the U.S. sales efforts for Palvella's upcoming QTORIN™ rapamycin, targeting microcystic lymphatic malformations, which is projected to provide the first FDA-approved treatment for over 30,000 diagnosed patients in the U.S., addressing a critical market gap.
- Strategic Development: Taylor's addition not only strengthens Palvella's market position in rare skin diseases and vascular malformations but also reflects the company's commitment to attracting top talent to drive business growth in high unmet need areas of dermatology.
- Product Pipeline: Palvella is developing multiple product candidates based on its QTORIN™ platform, and Taylor's extensive experience will help accelerate the market introduction of these products, particularly in areas lacking FDA-approved therapies, further enhancing the company's competitive edge.
See More
Palvella Appoints New Senior Vice President of Sales
- Executive Appointment: Palvella Therapeutics has appointed Kent Taylor as Senior Vice President of Sales, bringing over 25 years of pharmaceutical experience, having previously held executive roles at Arcutis Biotherapeutics and Incyte, where he successfully led the launches of ZORYVE® and OPZELURA®, which is expected to significantly enhance Palvella's sales leadership and market insight.
- Market Potential: Taylor will oversee the U.S. sales for Palvella's upcoming QTORIN™ rapamycin, targeting microcystic lymphatic malformations, which is anticipated to provide the first FDA-approved treatment for over 30,000 diagnosed patients in the U.S., addressing a significant unmet need in the market.
- Strategic Development: Taylor's addition not only strengthens Palvella's market position in rare skin diseases and vascular malformations but also reflects the company's commitment to attracting top talent, aiming to build a robust sales organization to support future product launches and market expansion.
- Industry Experience: Taylor's extensive experience in dermatology will facilitate closer collaborations with dermatologists, particularly pediatric dermatologists, further driving market acceptance and sales growth for the QTORIN™ platform.
See More
Biotech Landscape Update: Regulatory Approvals and Acquisitions
- ARS Pharma Expands Neffy Label: ARS Pharmaceuticals received FDA approval to update the Neffy 1mg label, removing age restrictions for individuals weighing over 33 lbs, which is expected to significantly boost market demand and enhance the company's competitive edge in allergy treatment.
- Novo Nordisk Wins Approval for Awiqli: Novo Nordisk's Awiqli (insulin icodec-abae) received FDA approval as the first once-weekly basal insulin, with a U.S. launch planned for 2H 2026, strengthening the company's leadership in diabetes care.
- Biogen Acquires Apellis: Biogen has agreed to acquire Apellis for $41 per share, valuing the deal at approximately $5.6 billion, which is expected to enhance its market share in immunology and rare diseases while driving future revenue growth.
- Takeda's Zasocitinib Clinical Trial Success: Takeda's Zasocitinib showed that about 70% of patients achieved significant skin clearance in Phase 3 trials, with plans to submit a New Drug Application in 2026, further solidifying its position in the dermatology market.
See More
Biotech IPOs Show Strong Performance in Q1 2026
- Biotech Financing Trends: In Q1 2026, biotech companies raised a median of $287.5 million each, with nearly all possessing mid to late-stage clinical data, indicating a strong market focus on high-value science that boosts investor confidence and capital inflow.
- Industry Focus on High-Value Projects: The IQVIA report reveals that pharmaceutical R&D spending reached $159.1 billion in 2025, with companies redirecting resources toward validated late-stage programs, reflecting a market preference for credible pipelines that enhances the standing of biotech firms.
- Avaí Bio's Major Progress: Avaí Bio is set to present new data on its α-Klotho anti-aging therapy at the Second Annual Klotho Conference, being invited to speak alongside renowned researchers, which signifies an elevation in its influence within the Klotho space and may attract increased investor attention.
- Stoke Therapeutics' Breakthrough Results: Stoke Therapeutics published data on zorevunersen in The New England Journal of Medicine, demonstrating its potential disease-modifying effects in Dravet syndrome, which is expected to propel its Phase 3 EMPEROR study in 2027, further solidifying its market position.
See More
Arcutis Biotherapeutics Executive Sells Shares
- Insider Share Sale: Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics on April 1, 2026, for a total value of $239,000, reducing his direct holdings to 39,744 shares, indicating a significantly diminished capacity for future sales.
- Transaction Scale Analysis: This sale of 10,000 shares aligns with the typical monthly trading volume observed since 2023, reflecting a consistent selling pattern from Welgus, and it represents 20% of his direct holdings, highlighting a notable decrease in his ownership stake.
- Company Financial Performance: Arcutis generated $372.1 million in net product revenue in 2025, a 123% increase year-over-year, with fourth-quarter sales reaching $127.5 million, indicating significant progress in its commercialization efforts and improving financial quality.
- Market Outlook: With the successful launch of ZORYVE eczema cream, Arcutis is transitioning from a development phase to a commercial phase, with a regulatory submission planned for 2026, suggesting that long-term investors should focus on the company's accelerating commercialization and expanding indications.
See More
Arcutis Biotherapeutics Director Sells Shares
- Director Share Sale: Howard G. Welgus, a director at Arcutis Biotherapeutics, sold 10,000 shares on April 1, 2026, for a total of $239,000, representing 20.10% of his direct holdings, reducing his stake from 49,744 to 39,744 shares, indicating sustained confidence in the company's future.
- Transaction Context: This sale was executed under a pre-arranged 10b5-1 plan adopted in March 2025, suggesting it was a planned liquidity event rather than a reaction to market fluctuations, especially with the stock up about 65% over the past year.
- Strong Financial Performance: Arcutis generated $372.1 million in net product revenue in 2025, a 123% year-over-year increase, with fourth-quarter sales alone reaching $127.5 million, demonstrating robust momentum in its commercialization efforts and expectations for continued positive operating cash flow.
- Clinical Data Validation: Recent Phase 2 data for ZORYVE cream showed meaningful improvements in infant atopic dermatitis, with rapid itch relief and strong tolerability, supporting a planned regulatory submission in 2026, further solidifying its market position in dermatological treatments.
See More
Palvella Appoints New Senior Vice President of Sales
- Executive Appointment: Palvella Therapeutics has appointed Kent Taylor as Senior Vice President of Sales, bringing over 25 years of pharmaceutical experience, including successful launches of innovative therapies at Arcutis Biotherapeutics and Incyte, which is expected to significantly enhance Palvella's sales leadership and market insights.
- Market Potential: Taylor will lead the U.S. sales efforts for Palvella's upcoming QTORIN™ rapamycin, targeting microcystic lymphatic malformations, which is projected to provide the first FDA-approved treatment for over 30,000 diagnosed patients in the U.S., addressing a critical market gap.
- Strategic Development: Taylor's addition not only strengthens Palvella's market position in rare skin diseases and vascular malformations but also reflects the company's commitment to attracting top talent to drive business growth in high unmet need areas of dermatology.
- Product Pipeline: Palvella is developing multiple product candidates based on its QTORIN™ platform, and Taylor's extensive experience will help accelerate the market introduction of these products, particularly in areas lacking FDA-approved therapies, further enhancing the company's competitive edge.
See More
Palvella Appoints New Senior Vice President of Sales
- Executive Appointment: Palvella Therapeutics has appointed Kent Taylor as Senior Vice President of Sales, bringing over 25 years of pharmaceutical experience, having previously held executive roles at Arcutis Biotherapeutics and Incyte, where he successfully led the launches of ZORYVE® and OPZELURA®, which is expected to significantly enhance Palvella's sales leadership and market insight.
- Market Potential: Taylor will oversee the U.S. sales for Palvella's upcoming QTORIN™ rapamycin, targeting microcystic lymphatic malformations, which is anticipated to provide the first FDA-approved treatment for over 30,000 diagnosed patients in the U.S., addressing a significant unmet need in the market.
- Strategic Development: Taylor's addition not only strengthens Palvella's market position in rare skin diseases and vascular malformations but also reflects the company's commitment to attracting top talent, aiming to build a robust sales organization to support future product launches and market expansion.
- Industry Experience: Taylor's extensive experience in dermatology will facilitate closer collaborations with dermatologists, particularly pediatric dermatologists, further driving market acceptance and sales growth for the QTORIN™ platform.
See More
Biotech Landscape Update: Regulatory Approvals and Acquisitions
- ARS Pharma Expands Neffy Label: ARS Pharmaceuticals received FDA approval to update the Neffy 1mg label, removing age restrictions for individuals weighing over 33 lbs, which is expected to significantly boost market demand and enhance the company's competitive edge in allergy treatment.
- Novo Nordisk Wins Approval for Awiqli: Novo Nordisk's Awiqli (insulin icodec-abae) received FDA approval as the first once-weekly basal insulin, with a U.S. launch planned for 2H 2026, strengthening the company's leadership in diabetes care.
- Biogen Acquires Apellis: Biogen has agreed to acquire Apellis for $41 per share, valuing the deal at approximately $5.6 billion, which is expected to enhance its market share in immunology and rare diseases while driving future revenue growth.
- Takeda's Zasocitinib Clinical Trial Success: Takeda's Zasocitinib showed that about 70% of patients achieved significant skin clearance in Phase 3 trials, with plans to submit a New Drug Application in 2026, further solidifying its position in the dermatology market.
See More
